Wednesday, 30 April 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 30 April 2025
News

Sanofi strikes out in patent battle

Posted 30 April 2025 AM

Sanofi has hit another obstacle to marketing its cholesterol drug Praluent in Australia, as the Federal Court upheld patents that could block the drug until at least 2028.

Federal Court Justice John Nicholas, who is set to retire, has dismissed Sanofi's appeal of the 2022 decision of an IP Australia delegate which granted patents to Amgen protecting Repatha. In the calendar year 2024 Repatha earned $54.1 million in pre-rebate R/PBS reimbursements.

To see the whole article, please login

Popular

One submission wonder hits PBS
71% of drugs pass PBAC muster
Yes... but with a price reduction
Sanofi strikes out in patent battle
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home